InnoCare shares results from phase 2 trial for atopic dermatitis treatment

Betsy Goodfellow | December 18, 2023 | News story | Research and Development |  Dermatology, InnoCare, atopic dermatitis, clinical trial 

InnoCare Pharma has announced phase 2 clinical trial results for its novel TYK2 (tyrosine kinase 2) inhibitor, ICP-332, which met its primary endpoint in adult patients with moderate-to-severe atopic dermatitis (AD).

The trial assessed ICP-332 in AD patients for four weeks, throughout which it demonstrated a strong efficacy and safety profile, meeting multiple endpoints including Eczema Area and Severity Index (EASI) 50, EASI 75, EASI 90 (improvement of at least 50%, 75% and 90% in EASI score for baseline) and Investigator’s Global Assessment (IGA) 0/1 (score of 0 ‘clear’ or 1 ‘almost clear’) in both the 80mg and/or 120mg dosing groups.

The trial was a randomised, double-blind, placebo-controlled phase 2 trial which aimed to assess the safety, efficacy, pharmacokinetics and pharmacodynamics of ICP-332 in patients with moderate-to-severe AD.

The drug also demonstrated a strong safety and tolerability profile, with most treatment-related adverse events being mild to moderate.

Dr Jasmine Cui, the co-founder, chair and chief executive officer of InnoCare Pharma, commented: “AD has huge unmet medical needs and we are excited to see the positive results from the phase 2 study of ICP-332. We will further accelerate the clinical development to benefit patients with AD and other autoimmune diseases.”

Betsy Goodfellow